Leerink Partnrs Reaffirms Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
by The Cerbat Gem
The Cerbat Gem— Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report sent to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 […]
The Cerbat Gem—AtriCure (NASDAQ:ATRC) Raised to Outperform at Oppenheimer. Oppenheimer upgraded shares of AtriCure (NASDAQ:ATRC – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday morning, Marketbeat.com reports. They currently have $32.00 target price on the medical device company’s stock. Other research analysts have also recently issued reports about the stock. Stifel Nicolaus […]
The Cerbat Gem—NETGEAR (NASDAQ:NTGR) Rating Reiterated by BWS Financial. NETGEAR (NASDAQ:NTGR – Get Free Report)‘s stock had its “neutral” rating reaffirmed by BWS Financial in a research note issued on Thursday, MarketBeat.com reports. They presently have a $13.00 price objective on the communications equipment provider’s stock. BWS Financial’s price target indicates a potential upside of 11.78% from the company’s current price. NETGEAR Stock Down […]
The Cerbat Gem—Beam Therapeutics (NASDAQ:BEAM) Shares Down 6.6%. Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) dropped 6.6% on Thursday . The stock traded as low as $20.84 and last traded at $21.23. Approximately 468,916 shares were traded during trading, a decline of 67% from the average daily volume of 1,435,909 shares. The stock had previously closed at $22.74. Wall Street Analysts Forecast […]